Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/34684| Title: | Letter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-it depends on how you use the drug. | Austin Authors: | Con, Danny;Srinivasan, Ashish | Affiliation: | Gastroenterology and Hepatology Department of Medicine, Faculty of Medicine, Dentistry & Health Sciences, The University of Melbourne, Melbourne, Australia. |
Issue Date: | Jan-2024 | Publication information: | Alimentary Pharmacology & Therapeutics 2024-01; 59(1) | URI: | https://ahro.austin.org.au/austinjspui/handle/1/34684 | DOI: | 10.1111/apt.17770 | ORCID: | 0000-0002-4983-6103 |
Journal: | Alimentary Pharmacology & Therapeutics | Start page: | 140 | End page: | 141 | PubMed URL: | 38085945 | ISSN: | 1365-2036 | Type: | Journal Article | Subjects: | Infliximab/therapeutic use Colitis, Ulcerative/diagnosis Colitis, Ulcerative/drug therapy Antibodies, Monoclonal, Humanized/therapeutic use |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.